Glennie MJ[au] - Search Results

Year	Number of Results
1982	1
1984	1
1985	3
1986	2
1987	7
1988	3
1989	1
1990	3
1991	9
1992	2
1993	2
1994	1
1995	6
1996	3
1997	5
1998	3
1999	4
2000	6
2001	5
2002	6
2003	7
2004	6
2005	2
2006	2
2007	4
2008	7
2009	6
2010	7
2011	5
2012	5
2013	9
2014	7
2015	10
2016	5
2017	4
2018	4
2019	3
2020	4
2021	1
2022	0

1

Influence of immunoglobulin isotype on therapeutic antibody function.

Beers SA, Glennie MJ, White AL. Beers SA, et al. Among authors: glennie mj. Blood. 2016 Mar 3;127(9):1097-101. doi: 10.1182/blood-2015-09-625343. Epub 2016 Jan 13. Blood. 2016. PMID: 26764357 Free PMC article. Review.

2

Rituximab: mechanisms and applications.

Johnson PW, Glennie MJ. Johnson PW, et al. Among authors: glennie mj. Br J Cancer. 2001 Nov 30;85(11):1619-23. doi: 10.1054/bjoc.2001.2127. Br J Cancer. 2001. PMID: 11742477 Free PMC article. Review. No abstract available.

3

Anti-CD20 monoclonal antibodies: historical and future perspectives.

Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Lim SH, et al. Among authors: glennie mj. Haematologica. 2010 Jan;95(1):135-43. doi: 10.3324/haematol.2008.001628. Epub 2009 Sep 22. Haematologica. 2010. PMID: 19773256 Free PMC article. Review.

4

Therapeutic potential of immunostimulatory monoclonal antibodies.

Gray JC, Johnson PW, Glennie MJ. Gray JC, et al. Among authors: glennie mj. Clin Sci (Lond). 2006 Aug;111(2):93-106. doi: 10.1042/CS20060024. Clin Sci (Lond). 2006. PMID: 16831129 Review.

5

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.

White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ. White AL, et al. Among authors: glennie mj. Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31. Cancer Immunol Immunother. 2013. PMID: 23543215 Review.

6

Signaling antibodies in cancer therapy.

Cragg MS, French RR, Glennie MJ. Cragg MS, et al. Among authors: glennie mj. Curr Opin Immunol. 1999 Oct;11(5):541-7. doi: 10.1016/s0952-7915(99)00010-2. Curr Opin Immunol. 1999. PMID: 10508709 Review.

7

Clinical trials of antibody therapy.

Glennie MJ, Johnson PW. Glennie MJ, et al. Immunol Today. 2000 Aug;21(8):403-10. doi: 10.1016/s0167-5699(00)01669-8. Immunol Today. 2000. PMID: 10916144 Review.

8

CD20 as a target for therapeutic type I and II monoclonal antibodies.

Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. Beers SA, et al. Among authors: glennie mj. Semin Hematol. 2010 Apr;47(2):107-14. doi: 10.1053/j.seminhematol.2010.01.001. Semin Hematol. 2010. PMID: 20350657 Review.

9

Mechanisms of killing by anti-CD20 monoclonal antibodies.

Glennie MJ, French RR, Cragg MS, Taylor RP. Glennie MJ, et al. Mol Immunol. 2007 Sep;44(16):3823-37. doi: 10.1016/j.molimm.2007.06.151. Mol Immunol. 2007. PMID: 17768100 Review.

10

Complement: help or hindrance?

Beers SA, Cragg MS, Glennie MJ. Beers SA, et al. Among authors: glennie mj. Blood. 2009 Dec 24;114(27):5567-8; author reply 5568. doi: 10.1182/blood-2009-10-249466. Blood. 2009. PMID: 20035044 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results